Pharnext SA
PAR:ALPHA
Pharnext SA
EPS (Diluted)
Pharnext SA
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharnext SA
PAR:ALPHA
|
EPS (Diluted)
-€26.3m
|
CAGR 3-Years
96%
|
CAGR 5-Years
86%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
EPS (Diluted)
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
EPS (Diluted)
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
15%
|
CAGR 10-Years
-1%
|
|
|
Inventiva SA
PAR:IVA
|
EPS (Diluted)
-€2
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
EPS (Diluted)
-$1
|
CAGR 3-Years
7%
|
CAGR 5-Years
27%
|
CAGR 10-Years
3%
|
|
|
Abivax SA
PAR:ABVX
|
EPS (Diluted)
-€3
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
Pharnext SA
Glance View
Pharnext SA develops and manufactures drugs for neurological diseases. The company is headquartered in Issy-Les-Moulineaux, Ile-De-France. The company went IPO on 2016-07-18. The firm is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The firm's prime focus is on neurodegenerative diseases and metabolic diseases.
See Also
What is Pharnext SA's EPS (Diluted)?
EPS (Diluted)
-26.3m
EUR
Based on the financial report for Jun 30, 2023, Pharnext SA's EPS (Diluted) amounts to -26.3m EUR.
What is Pharnext SA's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
86%
Over the last year, the EPS (Diluted) growth was 100%. The average annual EPS (Diluted) growth rates for Pharnext SA have been 96% over the past three years , 86% over the past five years .
